Clorox (NYSE: CLX), a consumer-products business that counts Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL) as related stocks, may have seen a sales drop of 1% in its fiscal first quarter, but that didn't stop it from posting a nice bottom-line growth rate. Clorox made $1.11 per share in Q1, and that represents a 23% increase. What a way to start a new corporate year!

According to Reuters, expectations were for 95 cents per share. That's a wonderful beat. Plus, sales volume went up 1%. Helping to drive things along was a healthy gross margin, as well as the dreaded H1N1 virus. Clorox has done well over the years associating its brand with sanitizing effectiveness, so when a pandemic rears its ugly head, the trademark is prepared to leverage such reputation to drive value.

Stocks suffered a scary drop on Friday. It was fitting, in a sense, since it was the day before Halloween. In fact, as this Closing Bell piece noted, there were more tricks than treats to be had on Wall Street.

There are always equities bucking the trend, however. The Estee Lauder Companies (NYSE: EL) was one of them. Bullish buyers loved the beauty company's fiscal Q1 earnings release. As has been the case with many reports, the top line wasn't the fun part of the document: Estee Lauder saw a decrease of 2.7% for adjusted revenues. Here's the item of interest: net income after charges was 85 cents per share, more than three times what was made in the comparable frame.

Avon Products (NYSE: AVP) had a difficult third quarter. Currency translations helped to drive a 4% decrease in net revenue. Excluding that effect, sales were up 7%. Net income decreased a big 31% to 36 cents per share.

However, according to Reuters, adjusted earnings of 42 cents per share beat analyst projections by two pennies. Such news didn't seem to matter to the market. At the time of this writing, Avon was down 1.9% on significant volume.

Kimberly-Clark Corporation (NYSE: KMB), a consumer products entity whose colleagues include Procter & Gamble (NYSE: PG) and Johnson & Johnson (NYSE: JNJ), is up today on third-quarter results. At the time of this writing, my screen was showing shares of Kimberly-Clark higher by a little under 6%.

According to the corporate press release, sales declined 1.7%. Not a great start, but Kimberly-Clark highlighted a better metric: organic sales increased 3%, helped along by price increases. Luckily, sales volume didn't fare too badly; they were essentially flat.

One of my wonderful friends, Ms. P, asked me for some guidance on how she might allocate $50,000 currently earning peanuts in a money market account. Though she is decades from becoming a grandmother, after a brief discussion about her financial parameters, it became clear to me that she was looking for a "granny fund."

In reality, my recommendations would be suitable, and perhaps desirable, for many passive investors as well.

The $50,000 is a portion of money Ms. P has set aside to purchase a home, which might happen in six months, but could also be pushed out further, depending on the economy and her situation. Basically, she wants to cover all her bases because she might need the money at any time and does not want to be caught short, while at the same time she would like to generate some revenue without taking any big risks.

If you are one of the investors out there watching General Motors stock each day trying to pick the perfect time to buy the stock... don't! For whatever reason, people have continued to buy General Motors stock, despite the fact that the company and the government have issued warnings that the stock is destined to be worthless.

I read an interesting article that reported yesterday there were 12.6 million shares of General Motors traded. Maybe people do not realize that the company went into bankruptcy, or maybe they are just trying to profit off of traders that are not aware that this is not new General Motors stock, but the volumes are a bit curious.

The Clorox Company (NYSE: CLX), a famous supermarket brand similar to companies such as Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL), reported Q4 earnings today. Excluding certain factors, Clorox increased its per-share profit by 18% to $1.35.

The dollar continues to wreak havoc on companies with international exposure (there's a whole lot of them, of course). Including currency translations, Clorox's top line was flat. Without the effect (and excluding the impact of a private-label business that the company exited), sales increased 3%. The company utilized price increases to help offset the tough times. Unfortunately, volume decreased 2% during the quarter.

Colgate-Palmolive (NYSE: CL), whose colleagues at the supermarket include companies like Procter & Gamble (NYSE: PG) and Clorox (NYSE: CLX), did all right in the second quarter. Sales were inhibited by currency rates: they dropped by well over 5%. The bottom line, on the other hand, fared a lot better. The company made $1.07 per share compared to 92 cents per share in the year-ago period. However, the previous year's quarter had 6 cents of charges to take into account, so the adjusted earnings in 2008 actually comes out to 98 cents. This makes the growth rate a modest 9%. The market was expecting $1.05 per share according to Earnings.com, so management beat by two pennies.

I was surprised a little by how the stock sold off on Thursday after the earnings report. Shares of Colgate-Palmolive closed down over 5% on very active volume.

Kimberly-Clark (NYSE: KMB), a consumer-products company that counts Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL) as colleagues, announced Q2 results on Thursday. The performance wasn't spectacular, but management successfully defended the bottom line from the recession by instituting pricing strategies that leveraged the brand equity of the company's portfolio.

The bottom line fell, of course, but probably not as far as it would have if there weren't any pricing mechanisms in place. Earnings per share came in at 97 cents. This was six cents lower than last year's adjusted Q2 income. Revenues were challenged by dollar fluctuations, dropping well over 5%. However, here's the silver lining: organic sales increased almost 3%, even with volumes on the decline.

Johnson & Johnson (NYSE: JNJ), a company that counts Procter & Gamble (NYSE: PG) and Pfizer (NYSE: PFE) as colleagues, will report results for the second quarter on Tuesday, July 14. JNJ is expected to post a bit of a profit decline. Last year's Q2, according to Earnings.com, saw the health-care business earn $1.18 per share. This time around, analysts are thinking that JNJ will do somewhere around $1.11 per share.

Will JNJ beat the analysts? It's quite possible, since the company has a good record on this count. As a matter of fact, JNJ beat predictions by four cents back in April. Sales, however, came in a little weak. Interestingly enough, the market didn't really care too much about the earnings performance on that day. Shares had rallied a bit in pre-market trading, but they closed slightly down by the end of the regular session. I found a similar situation back in January.

Consumer-products concern WD-40 (NASDAQ: WDFC) had something of a rough third quarter. According to the press release, which was issued on Wednesday after the bell, sales were down over 16%. The company made 41 cents per diluted share. This was 8 cents less than the previous year's Q3 performance.

It was, however, 3 cents better than what the analysts were looking for, according to Earnings.com. Gross margin, it should also be noted, improved significantly. Driving this positive element of the story were efficiencies in the supply chain, price increases, and the drop in the price of oil.

Analyst upgrades:

• Barclays believes Procter & Gamble's (NYSE: PG) portfolio mix provides better leverage to stabilizing macro trends. The firm upgraded shares to Overweight from Equal weight and raised its target to $60 from $56. Note the firm downgraded Colgate (NYSE: CL) to Equal Weight from Overweight.
• Deutsche Bank upgraded McDonald's (NYSE: MCD) to Buy from Hold as it finds the risk/reward on shares compelling at current levels and sees upcoming catalysts from McCafe and easing commodity pressures. The firm raised its target price to $65 from $60.
• FBR Capital upgraded Talbots (NYSE: TLB) to Outperform from Market Perform to reflect an attractive risk/reward, reduced risk of a bankruptcy, and merchandise improvements. The firm raised its target price to $4 from $2.
• Nokia (NYSE: NOK) was upgraded to Buy from Hold at Deutsche Bank.
• Analog Devices (NYSE: ADI) was upgraded to Neutral from Underperform at Baird.

Procter & Gamble (NYSE: PG) might not have the best growth rates going these days, but truth be told, I thought the company's Q3 report was acceptable given everything that is going on.

Yes, sales declined by 8%, driven by currency effects. Organic sales, however, increased 1%. Earnings per share increased 2% to 84 cents. This beat Wall Street forecasts by four pennies according to this source.

Energizer (NYSE: ENR), the famous battery company that competes with Procter & Gamble (NYSE: PG), reported Q2 earnings earlier today. According to this source, the results beat expectations on an adjusted basis. Energizer earned $1.12 per share. Analysts thought the business would do three pennies less.

Revenues, however, didn't fare so well. They fell 7%. Not only did the economy affect sales, but the dreaded currency-translation phantom that has been haunting the top lines of all businesses that are exposed to international transactions made its dreaded appearance on Energizer's earnings report. A conservative stance on the part of retailers and their inventory levels was also mentioned as a negative driver for sales in the release.

WD-40 (NASDAQ: WDFC), whose consumer-product colleagues include Procter & Gamble (NYSE: PG) and Clorox (NYSE: CLX), issued its second-quarter report on Wednesday after the market closed. The numbers were a bit rusty (yes, the bad pun was on purpose!).

First, we have a big net-sales drop of over 20%. Then, we have a 50% decline in net income, with earnings coming in at 25 cents per share. And finally, we see that the 25-cent per-share number missed estimates by two pennies according to this source. Management blamed the bad results in part on the weak global economy and on currency translations.